image
Healthcare - Medical - Devices - AMEX - US
$ 3.405
-3.36 %
$ 253 M
Market Cap
-2.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CATX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.4 USD, Perspective Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CATX stock under the base case scenario is HIDDEN Compared to the current market price of 3.4 USD, Perspective Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CATX stock under the best case scenario is HIDDEN Compared to the current market price of 3.4 USD, Perspective Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CATX

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.515 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
10.5 M OPERATING INCOME
125.55%
-79.3 M NET INCOME
-70.46%
-18.3 M OPERATING CASH FLOW
50.44%
-219 M INVESTING CASH FLOW
-898.25%
289 M FINANCING CASH FLOW
36764.33%
0 REVENUE
0.00%
-45 M OPERATING INCOME
-141.41%
-40.2 M NET INCOME
-165.63%
-26.6 M OPERATING CASH FLOW
-790.43%
-139 M INVESTING CASH FLOW
-366.09%
345 K FINANCING CASH FLOW
-45.06%
Balance Sheet Perspective Therapeutics, Inc.
image
Current Assets 231 M
Cash & Short-Term Investments 227 M
Receivables 116 K
Other Current Assets 4.13 M
Non-Current Assets 110 M
Long-Term Investments 0
PP&E 59.5 M
Other Non-Current Assets 50.4 M
66.52 %17.45 %14.78 %Total Assets$341.1m
Current Liabilities 18.2 M
Accounts Payable 0
Short-Term Debt 957 K
Other Current Liabilities 17.3 M
Non-Current Liabilities 32.2 M
Long-Term Debt 1.43 M
Other Non-Current Liabilities 30.8 M
34.25 %2.83 %61.02 %Total Liabilities$50.4m
EFFICIENCY
Earnings Waterfall Perspective Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 92.3 M
Operating Income 10.5 M
Other Expenses 89.7 M
Net Income -79.3 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)000(92m)10m(90m)(79m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-27.27% ROE
-27.27%
-23.24% ROA
-23.24%
3.15% ROIC
3.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Perspective Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -79.3 M
Depreciation & Amortization 2.31 M
Capital Expenditures -54.4 M
Stock-Based Compensation 5.39 M
Change in Working Capital 0
Others 55.4 M
Free Cash Flow -72.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Perspective Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CATX of $21.2 , with forecasts ranging from a low of $19 to a high of $24 .
CATX Lowest Price Target Wall Street Target
19 USD 458.00%
CATX Average Price Target Wall Street Target
21.2 USD 522.61%
CATX Highest Price Target Wall Street Target
24 USD 604.85%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Perspective Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
317 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
302 K USD 4
6-9 MONTHS
185 K USD 3
9-12 MONTHS
7. News
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. globenewswire.com - 2 weeks ago
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
Perspective Therapeutics to Participate in Upcoming May Investor Conferences SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com - 1 month ago
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT. globenewswire.com - 1 month ago
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 12, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. globenewswire.com - 2 months ago
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. globenewswire.com - 2 months ago
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 2 months ago
Perspective Therapeutics to Participate in Upcoming April Investor Conferences SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com - 2 months ago
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2024. globenewswire.com - 2 months ago
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. globenewswire.com - 3 months ago
Perspective Therapeutics to Present at Upcoming March Investor Conferences SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. globenewswire.com - 3 months ago
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. globenewswire.com - 3 months ago
8. Profile Summary

Perspective Therapeutics, Inc. CATX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 253 M
Dividend Yield 0.00%
Description Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Contact 350 Hills Street, Seattle, WA, 99354 https://www.perspectivetherapeutics.com
IPO Date Nov. 10, 2005
Employees 138
Officers Mr. Jonathan R. Hunt Chief Accounting Officer Mr. Andrew Bright Executive Vice President of Brachytherapy Mr. Amos Hedt BA, PGradDip Chief Business Strategy Officer Ms. Annie J. Cheng Vice President of Investor Relations Mr. Shane Cobb Executive Vice President of Operations Dr. Michael K. Schultz Ph.D. Chief Science Officer Mr. Chris Nenno General Counsel & Corporate Secretary Mr. Juan Graham Chief Financial Officer Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer Mr. Johan M. Spoor Chief Executive Officer & Director